Ovoca Bio Plc

AGM Information • Dec 1, 2023

National Storage Mechanism | Additional information

RNS Number : 4248V

Ovoca Bio PLC

01 December 2023

Ovoca Bio plc

("Ovoca" or the "Company")

Result of AGM

Dublin, Ireland, December 1, 2023 - Ovoca Bio, a biopharmaceutical company with a focus on women's health, announces that all resolutions proposed at the Company's Annual General Meeting held yesterday were passed. Voting on all resolutions was conducted by poll and the results are available on the Company's website at www.ovocabio.com.

The full text of the approved resolutions can be found in the Notice of the Annual General Meeting. The Notice is also available to view and download from the Company's website.

End

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com

Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)

Ivan Murphy / Daragh O'Reilly

Tel: +353 1 679 6363

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing Orenetide (BP-101), a novel synthetic peptide administered through a nasal spray as a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million premenopausal women in the US alone.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBBBDDRSGDGXB